LUCD实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 04:00):

Stats
今日成交量	275 028
平均成交量	174 998
市值	36.22M
EPS	$-0.250 ( 2024-03-26 )
下一个收益日期	( $-0.270 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00500 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.30
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

音量相关性

長: 0.04 (neutral)

短: -0.53 (weak negative)

Signal:(59.269) Neutral

Lucid Diagnostics Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lucid Diagnostics Inc. 相关性 - 货币/商品

0.71
( moderate )

0.00
( neutral )

-0.44
( neutral )

0.00
( neutral )

0.02
( neutral )

Lucid Diagnostics Inc. 财务报表

Annual	2023
营收:	$2.43M
毛利润:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
营收:	$2.43M
毛利润:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
营收:	$377 000
毛利润:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
营收:	$500 000
毛利润:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.